These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17785949)

  • 21. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Satraplatin: BMS 182751, BMY 45594, JM 216.
    Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.
    Mizugaki H; Yamamoto N; Fujiwara Y; Nokihara H; Yamada Y; Tamura T
    J Clin Oncol; 2015 Jun; 33(18):2051-61. PubMed ID: 25918301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status and future perspectives of cooperative study groups for lung cancer in Japan.
    Kawano Y; Okamoto I; Fukuda H; Ohe Y; Nakamura S; Nakagawa K; Hotta K; Kiura K; Takiguchi Y; Saka H; Okamoto H; Takayama K; Semba H; Kobayashi K; Kenmotsu H; Tsuboi M; Yamamoto N; Nukiwa T; Nakanishi Y
    Respir Investig; 2014 Nov; 52(6):339-47. PubMed ID: 25453377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [International clinical trials for a medical oncologist in Japan].
    Nakagawa K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):320-3. PubMed ID: 17301554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characteristics of clinical trials in oncology: pharmacist's implication].
    Madelaine-Chambrin I
    Ann Pharm Fr; 2006 Jan; 64(1):36-42. PubMed ID: 16449936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical trials of vnorelbine in breast cancer--its scientific usefulness and development history until regulatory approval].
    Tominaga T
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):541-7. PubMed ID: 16612169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects.
    Nagai S; Ozawa K
    Invest New Drugs; 2016 Dec; 34(6):777-791. PubMed ID: 27538583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Post launch studies].
    Akaza H; Ohashi Y; Shimada Y; Ikeda T; Saijo N; Isonishi S; Hirao Y; Tsuruo T; Tsukagoshi S; Sone S; Nakamura S; Kato M; Mikami O; von Euler M; Blackledge G; Milsted B; Vose B
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):2037-48. PubMed ID: 12465411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Participation of elderly patients in registration trials for oncology drug applications in Japan.
    Yonemori K; Hirakawa A; Komiyama N; Kouno T; Ando M; Fujiwara Y; Urano T; Akagawa H; Maruyama H; Toyoshima S
    Ann Oncol; 2010 Oct; 21(10):2112-2118. PubMed ID: 20332138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.
    Morgensztern D; Pennell NA; Subramanian J; Govindan R
    Clin Lung Cancer; 2011 Mar; 12(2):94-9. PubMed ID: 21550555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Contribution of Japan to develop new anticancer agents].
    Sajjo N
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):242-6. PubMed ID: 8611054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
    Reck M; Gatzemeier U
    Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knowledge of efficacy of treatments in lung cancer is not enough, their clinical effectiveness should also be known.
    Sekine I; Takada M; Nokihara H; Yamamoto S; Tamura T
    J Thorac Oncol; 2006 Jun; 1(5):398-402. PubMed ID: 17409889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unconventional anticancer agents: a systematic review of clinical trials.
    Vickers AJ; Kuo J; Cassileth BR
    J Clin Oncol; 2006 Jan; 24(1):136-40. PubMed ID: 16382123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.